Gleevec Indigent Patient Program Will Continue After Medicare Rx
Executive Summary
Novartis expects more than half of the patients currently receiving free doses of the oral oncologic Gleevec to qualify for the new Medicare prescription drug benefit in 2006
You may also be interested in...
House Committee Watching Genasense; Show Of Force During FDA Review
The House Energy & Commerce Committee is keeping a close watch on FDA's handling of the application for Aventis/Genta's Genasense
House Committee Watching Genasense; Show Of Force During FDA Review
The House Energy & Commerce Committee is keeping a close watch on FDA's handling of the application for Aventis/Genta's Genasense
Medicare Part B Demonstration Project Will Be Set In “Weeks” – CMS
The Centers for Medicare & Medicaid Services is "weeks" away from unveiling a $500 mil. demonstration project on coverage of alternatives to drugs reimbursed under Medicare Part B